Free Trial
NASDAQ:OVID

Ovid Therapeutics (OVID) Stock Price, News & Analysis

Ovid Therapeutics logo
$0.48 +0.02 (+3.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.49 +0.01 (+1.67%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ovid Therapeutics Stock (NASDAQ:OVID)

Key Stats

Today's Range
$0.45
$0.48
50-Day Range
$0.43
$0.91
52-Week Range
$0.42
$3.45
Volume
413,553 shs
Average Volume
420,129 shs
Market Capitalization
$33.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.20
Consensus Rating
Buy

Company Overview

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Remove Ads

Ovid Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

OVID MarketRank™: 

Ovid Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 83rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ovid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ovid Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Ovid Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ovid Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ovid Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ovid Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ovid Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.77% of the float of Ovid Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ovid Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ovid Therapeutics has recently increased by 0.88%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Ovid Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Ovid Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.77% of the float of Ovid Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ovid Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ovid Therapeutics has recently increased by 0.88%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Ovid Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Ovid Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for OVID on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ovid Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,971.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    13.30% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ovid Therapeutics' insider trading history.
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Stock News Headlines

Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst
Q2 EPS Estimates for Ovid Therapeutics Cut by William Blair
A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
What is Wedbush's Estimate for OVID FY2029 Earnings?
Equities Analysts Set Expectations for OVID Q1 Earnings
William Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
See More Headlines

OVID Stock Analysis - Frequently Asked Questions

Ovid Therapeutics' stock was trading at $0.9337 at the beginning of the year. Since then, OVID stock has decreased by 49.1% and is now trading at $0.4750.
View the best growth stocks for 2025 here
.

Ovid Therapeutics Inc. (NASDAQ:OVID) announced its quarterly earnings data on Tuesday, March, 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company earned $0.08 million during the quarter, compared to analysts' expectations of $0.19 million. Ovid Therapeutics had a negative trailing twelve-month return on equity of 39.24% and a negative net margin of 5,142.56%.

Ovid Therapeutics (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' top institutional shareholders include Takeda Pharmaceutical Co. Ltd. (10.61%), Madison Avenue Partners LP (5.24%), Kennedy Capital Management LLC (2.18%) and JPMorgan Chase & Co. (2.00%). Insiders that own company stock include Jeremy M Levin, Margaret A Alexander and Jason Tardio.
View institutional ownership trends
.

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Plug Power (PLUG), Alamos Gold (AGI), FuelCell Energy (FCEL), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Workhorse Group (WKHS).

Company Calendar

Last Earnings
3/11/2025
Today
3/19/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OVID
Fax
N/A
Employees
60
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$3.20
High Stock Price Target
$5.00
Low Stock Price Target
$1.20
Potential Upside/Downside
+609.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-52,340,000.00
Net Margins
-5,142.56%
Pretax Margin
-5,142.56%

Debt

Sales & Book Value

Annual Sales
$566,000.00
Price / Cash Flow
N/A
Book Value
$1.24 per share
Price / Book
0.36

Miscellaneous

Free Float
61,566,000
Market Cap
$32.05 million
Optionable
Optionable
Beta
0.29

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:OVID) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners